epilepsy

Lundbeck planning for four novel drugs in phase 3 in 2026
Pharmaphorum
Thu, 10/24/24 - 09:47 am
Lundbeck
R&D
new molecular entity
epilepsy
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
Fierce Biotech
Mon, 10/14/24 - 10:10 am
Longboard Pharmaceuticals
Lundbeck
M&A
epilepsy
bexicaserin
Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential
Fierce Biotech
Wed, 07/31/24 - 10:53 am
Takeda
epilepsy
soticlestat
earnings
J&J drops Addex-partnered epilepsy drug after reviewing failed phase 2 trial data
Fierce Biotech
Thu, 07/18/24 - 11:20 am
JNJ
Addex Therapeutics
epilepsy
ADX71149
Janssen
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
Fierce Biotech
Mon, 06/17/24 - 11:29 am
Takeda
clinical trials
Ovid Therapeutics
Dravet syndrome
epilepsy
soticlestat
Third Rock’s Rapport reveals upsized $154M IPO
Fierce Biotech
Fri, 06/7/24 - 11:30 am
Rapport Therapeutics
IPOs
epilepsy
Rapport talks up $122M IPO to support proof-of-concept epilepsy trials
Fierce Biotech
Mon, 06/3/24 - 10:32 pm
Rapport Therapeutics
IPOs
epilepsy
Sweet Harmony: Neuro biotech buys Epygenix and its epilepsy meds for $35M upfront
Fierce Biotech
Tue, 04/30/24 - 06:36 pm
Harmony Biosciencws
Epygenix
M&A
epilepsy
J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate
BioSpace
Mon, 04/29/24 - 10:56 pm
Addex Therapeutics
JNJ
ADX71149
epilepsy
clinical trials
Praxis’ epilepsy drug hits in phase 2, sparking stock rise and plans for next trial
Fierce Biotech
Tue, 03/26/24 - 11:34 am
Praxis Precision Medicines
clinical trials
PRAX-628
epilepsy
Neurona raises another $120M for brain disease cell therapies
BioPharma Dive
Thu, 02/8/24 - 09:55 pm
Neurona
funding
epilepsy
cell therapy
Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety
BioSpace
Tue, 10/10/23 - 11:33 am
Xenon
epilepsy
clinical trials
XEN1101
Stoke faces new doubts in search for ‘Spinraza for epilepsy’
BioPharma Dive
Tue, 07/25/23 - 08:47 pm
Stoke Therapeutics
Dravet syndrome
epilepsy
STK-001
Neurona’s brain stem cell therapy shows early efficacy in epilepsy
Clinical Trials Arena
Thu, 06/15/23 - 06:54 pm
Neurona
stem cells
epilepsy
clinical trials
Cerevel blames Covid for delayed neuroscience studies, says president is leaving
Endpoints
Fri, 02/24/23 - 09:12 am
Cerevel Therapeutics
COVID-19
epilepsy
Parkinson's Disease
darigabat
CVL-871
With bigger fish to fry, Eisai unloads US rights to epilepsy drug Fycompa to Catalyst
Fierce Pharma
Tue, 12/20/22 - 11:14 am
Eisai
Fycompa
Catalyst Pharmaceuticals
epilepsy
Praxis ends year on high with $100M biobucks UCB deal for epilepsy medicine
Fierce Biotech
Wed, 12/14/22 - 07:40 pm
Praxis
UCB Pharma
epilepsy
PRAX-020
Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite
Fierce Biotech
Wed, 11/9/22 - 10:41 am
Biohaven
Pfizer
funding
epilepsy
With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays
Fierce Biotech
Tue, 10/4/22 - 11:45 pm
Pfizer
Biohaven
migraines
epilepsy
Ovid takes a novel approach to gene therapy
EP Vantage
Thu, 08/25/22 - 10:54 am
Ovid Therapeutics
gene therapy
epilepsy
phages

Pages